Discovery Laboratories, Inc.
| Nasdaq: DSCO
Discovery Laboratories, Inc. is a biotechnology company developing surfactant therapies to treat respiratory disorders and diseases. Its novel KL4 proprietary technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for survival and normal respiratory function. The company's proprietary capillary aerosol-generating technology produces a dense aerosol with a defined particle size, to potentially deliver aerosolized KL4 surfactant to the lung. Discovery Laboratories products include Surfaxin, Surfaxin LS and Aerosurf. The company was founded in 1992 and is headquartered in Warrington, PA.